OncoFirm™ Diagnostics’ grant-funded research is centered on a combination of fluorescent lateral flow immunoassay technology, cancer biomarker detection, multiplex assay development, digital fluorescence readers, AI-assisted signal analysis, calibration and quality-control systems, and secure diagnostic data integration. These technologies are being developed to support laboratory research, analytical validation, clinical feasibility studies, and future regulatory development. Grant funding can help advance each component through defined scientific milestones, including assay optimization, biomarker validation, reader engineering, software development, manufacturing process control, and clinical research collaboration.
Laboratory Information System (LIS) Integration for Rapid Point-of-Care Diagnostics Seamless Laboratory Information System (LIS) Integration for Connected Healthcare At OncoFirm™ Diagnostics, we are implementing Laboratory Information System (LIS) integration framework…
Researchers applied MIGHT to liquid biopsy data, focusing on ccfDNA fragmentation patterns (e.g., fragment lengths, positions, and end motifs) to determine which features reliably indicate cancer: Challenge: False Positives Linked…
OncoFirm Diagnostics | https://oncofirmdiagnostics.com 1. Executive Summary The intersection of artificial intelligence (AI) and biomarker science is revolutionizing early cancer detection. By leveraging AI algorithms to analyze complex biological signals, OncoFirm…
Fluorescent LFA vs Traditional Testing
OncoFirm Diagnostics | https://oncofirmdiagnostics.com 1. Executive Summary Early detection of cancer remains one of the most cost-effective, life-saving interventions in modern medicine. However, millions globally still lack access to timely,…
AI-Driven Biomarkers: Transforming Cancer Detection Through Multimodal Intelligence Introduction The integration of artificial intelligence (AI) into healthcare has revolutionized biomedical research, diagnostics, and patient care. One of the most promising…
RNA Polymerase II Levels in Histone Genes: A Predictive Biomarker for Tumor Aggressiveness and Recurrence Introduction Histone genes play a fundamental role in DNA packaging and chromatin structure, and their…
OncoFirm™ Electronic Reader cassette reader* (detailed information coming soon)… Cutting-Edge Digital Cancer Diagnostics Solutions Lateral Flow Electronic Reader (LFER) technology is an advanced diagnostic tool used to enhance and quantify…
Thomsen–Friedenreich (TF) Antigen: A Key Marker in Cancer Biology The Thomsen–Friedenreich (TF) antigen, also known as CD176, is a simple two‑sugar structure (galactose + N‑acetylgalactosamine) normally hidden on healthy cells….
Our primary corporate website is now OncoFirm.com.
Visit our main website for the latest information about our cancer diagnostic technologies, research programs, intellectual property, corporate developments, partnerships and investor opportunities.
Continue to OncoFirm.com